Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/48518
Type
ArticleCopyright
Open access
Collections
- IOC - Artigos de Periódicos [12982]
Metadata
Show full item record
DIFFERENTIAL LONGEVITY OF MEMORY CD4 AND CD8 T CELLS IN A COHORT OF THE MOTHERS WITH A HISTORY OF ZIKV INFECTION AND THEIR CHILDREN
Author
Corrêa, Jessica Badolato
Carvalho, Fabiana Rabe
Paiva, Iuri Amancio
Macedo, Débora Familiar
Dias, Helver Gonçalves
Corrêa, Alex Pauvolid
Santos, Caroline Fernandes
Lima, Monique da Rocha Queiroz
Gandini, Mariana
Silva, Andréa Alice
Cavalcanti, Silvia Maria Baeta
Oliveira, Solange Artimos de
Vianna, Renata Artimos de Oliveira
Azeredo, Elzinandes Leal de
Cardoso, Claudete Aparecida Araújo
Grifoni, Alba
Sette, Alessandro
Weiskopf, Daniela
PInto, Luzia Maria de Oliveira
Carvalho, Fabiana Rabe
Paiva, Iuri Amancio
Macedo, Débora Familiar
Dias, Helver Gonçalves
Corrêa, Alex Pauvolid
Santos, Caroline Fernandes
Lima, Monique da Rocha Queiroz
Gandini, Mariana
Silva, Andréa Alice
Cavalcanti, Silvia Maria Baeta
Oliveira, Solange Artimos de
Vianna, Renata Artimos de Oliveira
Azeredo, Elzinandes Leal de
Cardoso, Claudete Aparecida Araújo
Grifoni, Alba
Sette, Alessandro
Weiskopf, Daniela
PInto, Luzia Maria de Oliveira
Affilliation
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Viral. Rio de Janeiro, RJ, Brasil.
Universidade Federal Fluminense. Escola de Medicina. Laboratório Multiusuário para Pesquisa em Nefrologia e Ciências Médicas. Niterói, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Viral. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Viral. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Viral. Rio de Janeiro, RJ, Brasil.
Department of Veterinary Integrative Biosciences, Texas A&M University, College Station. TX, USA / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Vírus Respiratório e do Sarampo. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Viral. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Viral. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Microbiologia Celular. Rio de Janeiro, RJ, Brasil.
Universidade Federal Fluminense. Escola de Medicina. Laboratório Multiusuário para Pesquisa em Nefrologia e Ciências Médicas. Niterói, RJ, Brasil.
Universidade Federal Fluminense. Instituto Biomédico. Laboratório de Diagnóstico Virológico. Niterói, RJ, Brasil.
Universidade Federal Fluminense. Escola de Medicina. Departamento Materno Infantil. Niterói, RJ, Brasil.
Universidade Federal Fluminense. Escola de Medicina. Departamento Materno Infantil. Niterói, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Viral. Rio de Janeiro, RJ, Brasil.
Universidade Federal Fluminense. Escola de Medicina. Laboratório Multiusuário para Pesquisa em Nefrologia e Ciências Médicas. Niterói, RJ, Brasil / Universidade Federal Fluminense. Escola de Medicina. Departamento Materno Infantil. Niterói, RJ, Brasil.
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI). San Diego, CA, USA.
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI). San Diego, CA, USA / Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, San Diego, CA, USA.
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI). San Diego, CA, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Viral. Rio de Janeiro, RJ, Brasil.
Universidade Federal Fluminense. Escola de Medicina. Laboratório Multiusuário para Pesquisa em Nefrologia e Ciências Médicas. Niterói, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Viral. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Viral. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Viral. Rio de Janeiro, RJ, Brasil.
Department of Veterinary Integrative Biosciences, Texas A&M University, College Station. TX, USA / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Vírus Respiratório e do Sarampo. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Viral. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Viral. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Microbiologia Celular. Rio de Janeiro, RJ, Brasil.
Universidade Federal Fluminense. Escola de Medicina. Laboratório Multiusuário para Pesquisa em Nefrologia e Ciências Médicas. Niterói, RJ, Brasil.
Universidade Federal Fluminense. Instituto Biomédico. Laboratório de Diagnóstico Virológico. Niterói, RJ, Brasil.
Universidade Federal Fluminense. Escola de Medicina. Departamento Materno Infantil. Niterói, RJ, Brasil.
Universidade Federal Fluminense. Escola de Medicina. Departamento Materno Infantil. Niterói, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Viral. Rio de Janeiro, RJ, Brasil.
Universidade Federal Fluminense. Escola de Medicina. Laboratório Multiusuário para Pesquisa em Nefrologia e Ciências Médicas. Niterói, RJ, Brasil / Universidade Federal Fluminense. Escola de Medicina. Departamento Materno Infantil. Niterói, RJ, Brasil.
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI). San Diego, CA, USA.
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI). San Diego, CA, USA / Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, San Diego, CA, USA.
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI). San Diego, CA, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Viral. Rio de Janeiro, RJ, Brasil.
Abstract
Background: Zika virus (ZIKV) infection causes for mild and self-limiting disease in
healthy adults. In newborns, it can occasionally lead to a spectrum of malformations,
the congenital Zika syndrome (CZS). Thus, little is known if mothers and babies with a
history of ZIKV infection were able to develop long-lasting T-cell immunity. To these issues,
we measure the prevalence of ZIKV T-cell immunity in a cohort of mothers infected to
the ZIKV during pregnancy in the 2016–2017 Zika outbreak, who gave birth to infants
affected by neurological complications or asymptomatic ones.
Results: Twenty-one mothers and 18 children were tested for IFN-γ ELISpot and T-cell
responses for flow cytometry assays in response to CD4 ZIKV and CD8 ZIKV megapools
(CD4 ZIKV MP and CD8 ZIKV MP). IFN-γ ELISpot responses to ZIKV MPs showed
an increased CD4 and CD8 T-cell responses in mothers compared to children. The
degranulation activity and IFN-γ-producing CD4 T cells were detected in most mothers,
and children, while in CD8 T-cells, low responses were detected in these study groups.
The total Temra T cell subset is enriched for IFN-γ+ CD4 T cells after stimulation of CD4
ZIKV MP.
Conclusion: Donors with a history of ZIKV infection demonstrated long-term CD4 T cell
immunity to ZIKV CD4 MP. However, the same was not observed in CD8 T cells with
the ZIKV CD8 MP. One possibility is that the cytotoxic and pro-inflammatory activities
of CD8 T cells are markedly demonstrated in the early stages of infection, but less
detected in the disease resolution phase, when the virus has already been eliminated. The Background: Zika virus (ZIKV) infection causes for mild and self-limiting disease in
healthy adults. In newborns, it can occasionally lead to a spectrum of malformations,
the congenital Zika syndrome (CZS). Thus, little is known if mothers and babies with a
history of ZIKV infection were able to develop long-lasting T-cell immunity. To these issues,
we measure the prevalence of ZIKV T-cell immunity in a cohort of mothers infected to
the ZIKV during pregnancy in the 2016–2017 Zika outbreak, who gave birth to infants
affected by neurological complications or asymptomatic ones.
Results: Twenty-one mothers and 18 children were tested for IFN-γ ELISpot and T-cell
responses for flow cytometry assays in response to CD4 ZIKV and CD8 ZIKV megapools
(CD4 ZIKV MP and CD8 ZIKV MP). IFN-γ ELISpot responses to ZIKV MPs showed
an increased CD4 and CD8 T-cell responses in mothers compared to children. The
degranulation activity and IFN-γ-producing CD4 T cells were detected in most mothers,
and children, while in CD8 T-cells, low responses were detected in these study groups.
The total Temra T cell subset is enriched for IFN-γ+ CD4 T cells after stimulation of CD4
ZIKV MP.
Conclusion: Donors with a history of ZIKV infection demonstrated long-term CD4 T cell
immunity to ZIKV CD4 MP. However, the same was not observed in CD8 T cells with
the ZIKV CD8 MP. One possibility is that the cytotoxic and pro-inflammatory activities
of CD8 T cells are markedly demonstrated in the early stages of infection, but less
detected in the disease resolution phase, when the virus has already been eliminated. The Background: Zika virus (ZIKV) infection causes for mild and self-limiting disease in
healthy adults. In newborns, it can occasionally lead to a spectrum of malformations,
the congenital Zika syndrome (CZS). Thus, little is known if mothers and babies with a
history of ZIKV infection were able to develop long-lasting T-cell immunity. To these issues,
we measure the prevalence of ZIKV T-cell immunity in a cohort of mothers infected to
the ZIKV during pregnancy in the 2016–2017 Zika outbreak, who gave birth to infants
affected by neurological complications or asymptomatic ones.
Results: Twenty-one mothers and 18 children were tested for IFN-γ ELISpot and T-cell
responses for flow cytometry assays in response to CD4 ZIKV and CD8 ZIKV megapools
(CD4 ZIKV MP and CD8 ZIKV MP). IFN-γ ELISpot responses to ZIKV MPs showed
an increased CD4 and CD8 T-cell responses in mothers compared to children. The
degranulation activity and IFN-γ-producing CD4 T cells were detected in most mothers,
and children, while in CD8 T-cells, low responses were detected in these study groups.
The total Temra T cell subset is enriched for IFN-γ+ CD4 T cells after stimulation of CD4
ZIKV MP.
Conclusion: Donors with a history of ZIKV infection demonstrated long-term CD4 T cell
immunity to ZIKV CD4 MP. However, the same was not observed in CD8 T cells with
the ZIKV CD8 MP. One possibility is that the cytotoxic and pro-inflammatory activities
of CD8 T cells are markedly demonstrated in the early stages of infection, but less
detected in the disease resolution phase, when the virus has already been eliminated. The responses of mothers’ T cells to ZIKV MPs do not appear to be related to their children’s
clinical outcome. There was also no marked difference in the T cell responses to ZIKV
MP between children affected or not with CZS. These data still need to be investigated,
including the evaluation of the response of CD8 T cells to other ZIKV peptides.
Share